Shao Z, Chu Y, Zhang Y, Chen G, Zheng Y
Institute of Hematology and Blood Disease Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin.
Am J Hematol. 1998 Nov;59(3):185-91. doi: 10.1002/(sici)1096-8652(199811)59:3<185::aid-ajh2>3.0.co;2-3.
To evaluate the therapeutic potential of hematopoietic growth factors (HGFs) during immunosuppressive treatment (IST) of severe aplastic anemia (SAA), 38 patients with newly diagnosed SAA received IST alone (group I), or IST plus recombinant human erythropoietin and granulocyte-macrophage colony-stimulating factor (rhEPO + rhGM-CSF) (group II). Eleven patients in each group received antilymphocyte globulin (ALG) for IST, and eight patients in each group received cyclosporine (CSA). Complete remission rates at one year were 26% and 74% for group I and group II patients, respectively. The ALG-treated subgroup showed the greatest differences between treatments. Compared with patients receiving ALG alone, patients treated with ALG plus HGFs had significantly better one-year survival (100% vs. 54.5%, P < 0.05), complete remission rates (91% vs. 36%, P < 0.05), more rapid and complete hematologic recovery, greater reductions in transfusion requirements, and lower infection rates. The data suggest a potential role for rhEPO + rhGM-CSF therapy in SAA patients receiving IST.
为评估造血生长因子（HGFs）在重型再生障碍性贫血（SAA）免疫抑制治疗（IST）期间的治疗潜力，38例新诊断的SAA患者单独接受IST（I组），或接受IST联合重组人促红细胞生成素和粒细胞-巨噬细胞集落刺激因子（rhEPO + rhGM-CSF）（II组）。每组11例患者接受抗淋巴细胞球蛋白（ALG）进行IST治疗，每组8例患者接受环孢素（CSA）治疗。I组和II组患者一年时的完全缓解率分别为26%和74%。接受ALG治疗的亚组显示出治疗之间的最大差异。与单独接受ALG治疗的患者相比，接受ALG加HGFs治疗的患者一年生存率显著更高（100%对54.5%，P < 0.05），完全缓解率更高（91%对36%，P < 0.05），血液学恢复更快且更完全，输血需求减少更多，感染率更低。数据表明rhEPO + rhGM-CSF治疗在接受IST的SAA患者中具有潜在作用。
